As Per the Research Report, the Europe Immunotherapy Drugs Market Size is valued at USD 20.33 billion in 2021 and is forecasted to reach USD 33.64 billion by 2026, growing at a CAGR of 10.6% during the forecast period 2021 to 2026.
The usage of immunotherapy drugs is on the rise with the increases cases of cancer and autoimmune diseases. And also, owing to its lesser side effects, the market is likely to propel in the forecast period.
Immunotherapy is a way of treating cancer by enhancing the innate power of the immune system. The treatment involves using the individual’s own immune system to fight cancer cells. It either stimulates the function of each particular component of the immune system or acts against the signals caused by the cancer cells suppressing the responses by the immune system. These properties of the immunotherapy drugs to be able to aid the immune system fight against the abnormal cells make them being successfully used against diseases like infection, cancer, autoimmune and respiratory disorders.
Rising incidences of cancer and other autoimmune diseases have led to innovations in the development of drugs with the help of technological advancements. The other factors responsible for the growth of the market include emergence of biosimilars, higher efficacy than the common drugs with lower side effects and reduction in the overall time of developing and testing new drugs. However, the market is restrained by the higher cost related to the treatment and lower accessibility.
Europe Immunotherapy Drugs Market has been segmented and sub-segmented into the following categories
Top Companies leading the Europe Immunotherapy Drugs Market Profiled in the Report are Roche, Merck, Eli Lilly, Novartis, AstraZeneca, GlaxoSmithKline PLC, Amgen, Celgene, Bristol Myers Squibb, and Seattle Genetics.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Drug Type
5.1.1 Monoclonal Antibodies
5.1.2 Interferons
5.1.3 Interleukins
5.1.4 Vaccines
5.1.5 Checkpoint Inhibitors
5.2 By Application
5.2.1 Blood Cancer
5.2.2 Cervical Cancer
5.2.3 Breast Cancer
5.2.4 Glioblastoma
5.2.5 Lung Cancer
5.2.6 Gastric Cancer
5.2.7 Prostate Cancer
5.2.8 Melanoma
6. Geographical Analysis
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.
8. Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9. Market Leaders' Analysis
9.1 Eli Lilly
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Financial analysis
9.1.4 Recent Developments
9.1.5 SWOT analysis
9.1.6 Analyst View
9.2 Merck
9.3 Roche
9.4 Amgen
9.5 Novartis
9.6 Celgene
9.7 AstraZeneca
9.8 Bristol Myers Squibb
9.9 GlaxoSmithKline PLC
9.10 Seattle Genetics
10. Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
